(Q34074919)

30 July 2017

1 reference

title

An update on satraplatin: the first orally available platinum anticancer drug (English)

1 reference

30 July 2017

1 reference

1 reference

Kelland LR

1

1 reference

PubMed ID

11060749

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

1 reference

30 July 2017

9

1 reference

30 July 2017

6

1 reference

30 July 2017

1373-1382

1 reference

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin

30 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

A new orally active antitumor 1 R ,2 R -cyclohexanediamine-platinum(IV) complex: trans -( n -valerato)chloro(1 R ,2 R -cyclohexanediamine) (oxalato)platinum(IV)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1373

10.1517/13543784.9.6.1373

21 January 2018

Identifiers

DOI

1 reference

release_h3h5xhai4rg6fbegeuv6u3tfoa

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h3h5xhai4rg6fbegeuv6u3tfoa

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

11060749

1 reference

PubMed ID

11060749